A Study of the Efficacy and Safety of Tocilizumab for Confirmed Rheumatoid Arthritis (RA) Participants in Clinical Practice

Roche

Status: Terminated

Conditions: Rheumatoid Arthritis

Treatments: Other: No intervention

Study type: Observational

Funder types: Industry

Identifiers

NCT02616328

ML29936

Details and patient eligibility

About

This is a single-arm, open-label, non-randomized, multicenter trial to evaluate the efficacy and safety of using tocilizumab for confirmed rheumatoid arthritis participants in clinical practice.

Enrollment: 8 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosed with moderate-to-severe active rheumatoid arthritis (RA) for over 3 months
• Started on tocilizumab, with or without previous history of biological treatment

Exclusion criteria

• Pregnant or lactating women
• Treated with an investigational drug within 30 days prior to initiation of study drug
• Having a condition that, in the opinion of the investigator, could compromise the participant's safety or interfere with the study results

Trial design

8 participants in 1 patient group

Participants with confirmed rheumatoid arthritis

Treatment:

Other: No intervention